Neumora Therapeutics, Inc. Common Stock (NMRA)の価格はいくらですか

Neumora Therapeutics, Inc. Common Stock (NMRA)の価格は$1.38です

Neumora Therapeutics, Inc. Common Stock (NMRA)の時価総額は何ですか

Neumora Therapeutics, Inc. Common Stock (NMRA)の時価総額は$254.97Mです

Neumora Therapeutics, Inc. Common Stock（NMRA）の株価履歴

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

年	パフォーマンス
2026 (TTM)	4.73%
2025	-81.20%
2024	-26.84%
2023	0.00%

年

パフォーマンス

2026 (TTM)

4.73%

2025

-81.20%

2024

-26.84%

2023

0.00%

企業	株価	変化率 1年%	国
Vertex Pharmaceuticals Incorporated VRTX.US	$550.56	37.30%	US
Argenx SE ARGX.US	$1.05K	47.97%	NL
CSL Limited CSL.AX	$122.21	-10.03%	AU
Moderna, Inc. MRNA.US	$146.95	507.48%	US
Lonza Group AG LONN.SW	$757.71	8.20%	CH

企業

株価

変化率 1年%

国